Cerus Corp (CERS)

NASD · Healthcare · Medical Devices · USA

Cerus Corp is a small cap company (market value between $300 million and $2 billion) in the Medical Devices industry.

Cerus Corp offers the INTERCEPT Blood System, a biomedical product designed to inactivate pathogens in blood donations intended for transfusion. The platelet and plasma variants have obtained FDA approval and CE certification and are sold across multiple countries worldwide. The company also provides systems for cryoprecipitation and an LED-based illuminator.

From its FY2025 annual report (Form 10-K)

Intrinsic value, DCF valuation, financial health and value investing analysis for the Cerus Corp stock.

Our verdict on CERS

Undervalued: intrinsic value $2.57 per share, market price $1.90, margin of safety 26.2% (as of 2026-11-17).

A 2.4x revenue multiple, discounted for its losses, values the shares at $2.57; the price of $1.90 is 26% below that value.

ETFs with the most weight in CERS

17 more funds hold it; the full list is part of the paid plan.

More on CERS

Browse

Peers in Medical Devices

All 140 Medical Devices stocks

Cheaper than CERS in Medical Devices

5 more in this industry show a wider margin of safety.

Is CERS undervalued or overvalued?

CERS is undervalued (as of the 2026-11-17 close). A 2.4x revenue multiple, discounted for its losses, values the shares at $2.57; the price of $1.90 is 26% below that value.

What is the intrinsic value of CERS?

$2.57 per share (as of the 2026-11-17 close), against a market price of $1.90. That is a margin of safety of 26.2%. The value comes from the one valuation method that applies to this company, recomputed every night after the US close.